Clinical evidence supporting rituximab
Won Seog Kim
Is the era of chemotherapy over in CLL?
John Gribben et al.
Big data on efficacy and toxicity levels for ibrutinib in CLL
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Lymphoid Highlights from BSH 2017